Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | P2RX4 | Q99571 | 11/20 | 0.37 |
| ▸ | CYP2C8 | P10632 | 1/20 | 0.37 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.37 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.37 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.37 |
| ▸ | HTR2C | P28335 | 1/20 | 0.37 |
| ▸ | P2RX3 | P56373 | 1/20 | 0.37 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.37 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.37 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.37 |
| ▸ | PTGDR2 | Q9Y5Y4 | 7/20 | 0.36 |
| ▸ | PTGDR | Q13258 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL347634 | 0.93 | CYP3A4 (0.47) | CYP3A4P2RX4CYP2C8CYP2D6CYP2C9 | |
| SCHEMBL349083 | 0.92 | CYP3A4 (0.40) | CYP3A4P2RX4CYP2C8CYP2D6CYP2C9 | |
| SCHEMBL10129303 | 0.83 | CYP3A4 (0.61) | CYP3A4P2RX4CYP2C8CYP2D6CYP2C9 | |
| SCHEMBL1572613 | 0.82 | CYP3A4 (0.48) | CYP3A4P2RX4CYP2C8CYP2D6CYP2C9 | |
| SCHEMBL12375393 | 0.81 | CYP3A4 (0.45) | CYP3A4P2RX4CYP2C8CYP2D6CYP2C9 | |
| SCHEMBL349244 | 0.79 | CYP3A4 (0.45) | CYP3A4P2RX4CYP2C8CYP2D6CYP2C9 | |
| SCHEMBL13521968 | 0.78 | CYP3A4 (0.51) | CYP3A4P2RX4CYP2C8CYP2D6CYP2C9 | |
| SCHEMBL349800 | 0.78 | CYP3A4 (0.54) | CYP3A4P2RX4CYP2C8CYP2D6CYP2C9 | |
| SCHEMBL350021 | 0.77 | CYP3A4 (0.47) | CYP3A4P2RX4CYP2C8CYP2D6CYP2C9 | |
| SCHEMBL348006 | 0.77 | CYP3A4 (0.69) | CYP3A4PTGDR2PTGDR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8247602-B2 | Antagonists of prostaglandin D2 receptors | PANMIRA PHARMACEUTICALS, LLC (US) | 2012-08-21 | — | — | US | disclosed |
| US-20120016029-A1 | ANTAGONISTS OF PROSTAGLANDIN D2 RECEPTORS | PANMIRA PHARMACEUTICALS, LLC (US) | 2012-01-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120016029-A1 | ANTAGONISTS OF PROSTAGLANDIN D2 RECEPTORS | PTGDR, PTGDR2, PTGER2 | CYP3A4 1441/4885P2RX4 336/4885CYP2C8 613/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.